Trie authors investigated whether two objective allergy markers, peripheral blood eosinophilia and skin tests for common aeroallergens, were associated with cardiovascular death. Of 5,382 subjects in the VlagtweddeVlaardingen Study (the Netherlands) with data on allergy markers in 1965-1972, 507 subjects died from cardiovascular disease during 30 years of follow-up. Subjects with eosinophilia had an increased risk of cardiovascular death (relative risk (RR) = 1.7; 95% confidence interval (Cl): 1.4, 2.2), including ischemic heart disease death (RR = 1.6; 95% Cl: 1.2, 2.2) and cerebrovascular death (RR = 2.3; 95% Cl: 1.4, 3.8), independent of major risk factors. This association was limited to subjects with a percentage of the predicted forced expiratory volume in 1 second (FEV, % predicted) of <100%. Positive skin tests were associated with a significantly reduced cardiovascular mortality in subjects with normal lung function and weight who did not smoke (RR = 0.15; 95% Cl: 0.05, 0.46). Conversely, when subjects with positive skin tests had a body mass index of £25 kg/m 2 , had an FEV, % predicted of <80%, or smoked, they had an increased risk for cardiovascular mortality. These results were not restricted to asthmatics. Our data suggest a possible link between eosinophilia and positive skin tests and cardiovascular mortality, especially in combination with other risk factors associated with its mortality. Am J Epidemiol 1999;150:482-91.
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allergens; cardiovascular diseases; cohort studies; eosinophilia; eosinophils; mortality; population; skin tests Smoking, hypertension, and hypercholesterolemia are established risk factors for cardiovascular disease (1) (2) (3) (4) . Other factors including physical inactivity (1), diabetes mellitus (1), high body mass index (3) , and low percentage of the predicted forced expiratory volume in 1 second (FEV,) (5, 6) are also associated with increased risk of cardiovascular disease. However, other yet unrecognized factors must play a role, since these risk factors do not explain all prevalence of cardiovascular disease (2, 4) .
Allergy might be such a factor (7) . Type I allergy or atopy occurs frequently in the population and has been reported to be increasing in Western countries (8) . Therefore, an association between allergy and cardiovascular disease is potentially important Allergy can be studied subjectively by using questionnaires or objectively by using biologic markers, i.e., peripheral blood eosinophil counts, total and specific serum irnmunoglobulin E levels, and skin tests. Prentice et al. (9) showed that the eosinophil fraction of the total leukocyte count was associated with increased coronary heart disease incidence after adjustment for total leukocyte count but not for smoking habits. They further showed that at a specified leukocyte count the estimated coronary heart disease risk increased as the eosinophil fraction relative to the neutrophil fraction increased. Recently, Sweetnam et al. (10) reported that, besides total leukocyte count and neutrophil count, an elevated peripheral blood eosinophil count also was associated with an increased incidence of ischemic heart disease. They did not adjust for total leukocyte count or neutrophil count (10) , but their results were adjusted for smoking, a well-known risk factor for cardiovascular disease (11) . In contrast with the former two studies, Olivares et al. (12) found no association between the leukocyte subpopulations eosinophilia and neutrophilia, analyzed as absolute and proportional counts, and incidence of ischemic heart disease (only 46 cases) after adjustment for age and smoking. It is, therefore, a controversial issue whether smoking influences the association between eosinophilia and the incidence of ischemic heart disease.
A similar argument holds for reduced levels of lung function. Low FEVj is associated with a higher peripheral blood eosinophil count (13, 14) and with a higher incidence of cardiovascular disease, independent of smoking (5, 6, 15, 16) . On the basis of clinical observations, Rozencwaig (7) suggested a higher incidence of cardiovascular disease in patients with positive allergy tests, but the fact that he did not adjust for other risk factors for cardiovascular disease may have confounded the association between allergy and the incidence of cardiovascular disease. Cardiovascular disease is the most important cause of death in Western countries. Smoking and FEV, are not only associated with cardiovascular disease but also with cardiovascular mortality (6, 17) .
We were interested whether subjects with objective allergy markers, peripheral blood eosinophilia and/or positive skin tests to common aeroallergens, have increased cardiovascular mortality from ischemic and cardiovascular diseases other than ischemic heart disease, after adjustment for major risk factors. We also investigated whether these associations were restricted to asthmatic individuals, since allergy exists in almost all patients with asthma (18) .
MATERIALS AND METHODS

Population
The Vlagtwedde-Vlaardingen Study is an epidemiologic field study of risk factors for asthma and chronic obstructive pulmonary disease in a random sample of the inhabitants of two Dutch communities. The population selection has been described previously (19, 20) . Briefly, in 1965 this study was carried out in Vlagtwedde, a rural area in the northeast, and in Vlaardingen, an urban area in the western part of the Netherlands, in subjects aged 40-64 years, followed by a survey of young people aged 15-39 years in 1967 in Vlagtwedde and in 1969 in Vlaardingen. In some cases, eosinophil counts were not available in the first survey but were available in the first follow-up survey in 1970 in Vlagtwedde or in 1972 in Vlaardingen, and in those cases data from the first follow-up were used (629 cases). A total of 6,378 subjects had a peripheral blood eosinophil count available, and 6,324 had both a peripheral blood eosinophil count and skin tests available; 117 subjects were excluded because of missing data on lung function, smoking, weight, or asthma status. Because of the unsatisfactory quality (n = 795) or lack of an assessment (n = 30) of the spirogram, another 825 subjects were excluded. A total of 5,382 men and women had peripheral blood eosinophil counts, skin tests, and complete data for all other covariates.
Peripheral blood eosinophil count
Peripheral blood eosinophil counts were assessed in a 1:11 dilution of peripheral blood using a Biirker counting chamber (18, 20) . Eosinophilia was defined as >275 cells/mm 3 of blood, a cutoff point based on the investigation by Veening (21) .
Allergen skin testing
Four common aeroallergens were applied intracutaneously to the volar forearm: house dust, mixed pollen, epidermal products, and mixed molds (20, 22) . Wheal diameters for each allergen were measured to the nearest 0.5 mm and coded on a six-point scale (0 = 0-5 mm, 1 = 5.1-7.5 mm, 2 = 7.6-10 mm, 3 = 10.1-12.5 mm, 4 = 12.6-15 mm, 5 = >15 mm). Scores for the four allergens were added to a skin test sum score (range, 0-20). Positive skin tests were defined as a skin test sum score of >3 (18) . A histamine biphosphate solution was used as a positive control (20, 22) . Eight subjects had no data on the positive control, and 391 subjects had no reaction to the positive control.
Body mass Index
Body mass index was calculated as weight (kg)/height (m) 2 and divided into four classes according to World Health Organization criteria: underweight, <18.50; normal weight, 18.50-24.99; overweight, 25.00-29.99; and obesity >30 kg/m 2 (23).
Questionnaire
Data on age, sex, smoking habits, and respiratory symptoms were collected by means of a Dutch version of the British Medical Research Council's standard questionnaire (24) (25) (26) . Interviews were performed by trained interviewers. Smoking was considered as a categorical variable; exsmokers had stopped smoking at least 1 month before the examination, and current smokers smoked >1 cigarette a day. Pipe and cigar smokers were also considered as smokers. Asthma was considered to be present if an affirmative answer was given to the question of whether a subject had ever experienced attacks of shortness of breath with wheezing at rest (asthma attacks). Thus, asthma was self-reported and not physician-diagnosed asthma.
Splrometry
FEV, was assessed with a water-sealed spirometer (D 53; Lode Instruments, Groningen, the Netherlands). Measurement of inspiratory vital capacity after a deep expiration was followed by the measurement of FEV r Subjects performed the maneuver until two technically satisfactory tracings were produced, the higher value of these tracings being taken as the baseline measurement (13, 20) . The percent predicted reference values were calculated with regression coefficients derived from analysis of our own population data. For all asymptomatic subjects regardless of their smoking habits who took part in the 1965/1967/1969 survey 1 or, when no complete data for all covariates were available from this first survey, in the 1970/1972 survey 2, we computed regression equations for REV, as a function of age and height, with an age cutoff of 21 years for both sexes separately. The actual measured FEV, value was expressed as the percentage of the predicted FEV,. FEV, was used in the analyses as <80 percent of predicted for subjects with reduced and as >80 percent of predicted for subjects with (near) normal lung function, as reported by Lange et al. (6) . The latter group was divided into subgroups with near normal (80-99.99 percent) and normal (^100 percent of the FEV, percent predicted) lung function.
Follow-up
Until March 10, 1995, subjects were traced for their vital status (alive, dead, lost to follow-up) with 99 percent success (4,172 alive and 1,135 dead); only 75 subjects (1 percent) were lost to follow-up. Survival time was calculated for each subject from the date of entry into the study (between 1965 and 1972) until the end of follow-up at one of the following three times: 1) March 10, 1995, for subjects registered at the municipalities as being ah've; 2) the date of death for subjects identified in the Death Register of the municipalities; or 3) the last registration of subjects lost to follow-up, for example, date of last survey attended or date of move when the new address could not be traced. Causes of death were obtained from the Netherlands Central Bureau of Statistics in Voorburg. Cardiovascular death was classified according to International Classification of Diseases (ICD) codes for cardiovascular disease during 1965-1995: ICD, Revisions 7, 8, and 9 (ICD-7, ICD-8, and ICD-9, respectively). Cardiovascular death was divided into that due to ischemic and cardiovascular diseases other than ischemic heart disease, with the latter group subdivided into death due to cerebrovascular and other cardiovascular diseases. This last subgroup included death due to rheumatic heart disease, diseases of the arteries, hypertensive disease, other heart disease, other diseases of the vascular system, pulmonary embolism, and (sub)acute endocarditis according to the classification of Mackenbach et al. (27, 28 ) (see Appendix).
Statistical analyses
Associations between the allergy markers and mortality from cardiovascular disease were estimated with the Cox proportional hazard model (29) . Time was defined from the initial examination until the endpoint of interest, either cardiovascular death or one of its subgroups. Censoring took place when the subjects were still alive at March 10,1995, were lost to followup (only 1 percent), or died from another cause (30) . A proportional hazards model accounts for varying intervals in follow-up among subjects (e.g., censoring) and permits for control the potential confounding effects of other risk factors. Analyses were performed with simultaneous adjustment for city (Vlaardingen vs. Vlagtwedde), sex, age, smoking habits, FEV, percent predicted, and body mass index at the start of the study (table 3) . Analyses were repeated for the two subgroups of cardiovascular death, ischemic and cardiovascular diseases other than ischemic heart disease, and for the two subgroups of death due to cardiovascular diseases other than ischemic heart disease, cerebrovascular death and death due to other cardiovascular disease. Differences among subgroups of sex, age, smoking habits, lung function, body mass index, and city were tested by inclusion of an interaction term with the allergy markers in the model. In addition, we added a history of asthma attacks to this model, as both a single term and a term for interaction with the allergy markers, to test whether subjects with both allergy and asthma had a higher risk of mortality from cardiovascular disease. If an interaction with one of these covariables was statistically significant (p value < 0.05), it was added to the model (table 4) . Table 1 shows the population characteristics at the start of the study stratified by the absence or presence of eosinophilia and positive skin tests. Twelve percent (662 subjects) had eosinophilia, and 15 percent (834 subjects) had positive skin tests. Only 3 percent (161 subjects) had both eosinophilia and positive skin tests. Subjects with eosinophilia were more often male, smoked more often, had lower levels of FEV, percent predicted, had more often a history of asthma attacks, and lived more often in Vlaardingen than did subjects without eosinophilia. Subjects with positive skin tests were more often male, smoked more often, were younger, had a lower body mass index, had more often a history of asthma attacks, and lived more often in Vlaardingen than did subjects without positive skin tests. Table 2 shows that, of the 1,135 deaths occurring during follow-up, 507 (45 percent) were due to cardiovascular disease: 89 (51 percent) in the group with eosinophilia and 44 (43 percent) in the group with positive skin tests. There were 303 deaths (27 percent) from ischemic heart disease, 51 (29 percent) in the group with eosinophilia and 25 (25 percent) in the group with positive skin tests. There were 204 deaths (18 percent) from cardiovascular diseases other than ischemic heart disease (nonischemic heart death in the table), of which 95 (8 percent) died from cerebrovascular disease and 109 (10 percent) subjects died from other cardiovascular disease.
RESULTS
Eosinophilia was associated with an increased risk for death from cardiovascular disease (relative risk (RR) = 1.73; 95 percent confidence interval (CI): 1.37, 2.18), independent of skin tests, sex, age, smoking habits, FEV, percent predicted, body mass index, and city at the start of the study (table 3) . This increased mortality risk was present for both ischemic heart disease (RR = 1.64; 95 percent CI: 1.21, 2.23) and cardiovascular diseases other than ischemic heart disease (RR = 1.92; 95 percent CI: 1.34, 2.74). In the latter group, death from cerebrovascular disease (RR = 2.30; 95 percent CI: 1.39, 3.79) was significantly increased.
In contrast, the presence of positive skin tests was not associated with increased mortality from all cardiovascular diseases (RR = 1.03; 95 percent CI: 0.75, 1.42) or any of the subgroups. The association between eosinophilia and cardiovascular mortality was not different for subjects with and without positive skin tests. Furthermore, sex, age, smoking, FEV, percent predicted, and body mass index were all associated with increased mortality from cardiovascular disease and ischemic heart disease, but not the variables exsmoking and city. Smoking and overweight were not associated with death due to cardiovascular diseases other than ischemic heart disease (nonischemic deaths in table 3) and its subgroups. In contrast, underweight (body mass index of <18.50 kg/m 2 ) was associated with death due to cardiovascular diseases other than ischemic heart disease and its subgroups and not with ischemic heart death. Finally, subjects in Vlaardingen had a significantly increased risk for death from cardiovascular diseases other than ischemic heart disease.
When the presence of self-reported asthma and the interaction terms of asthma with the allergy markers were added to this model, the associations of eosinophilia and increased risk of cardiovascular death and its subgroups remained unchanged (table 3, lower panel). The association between positive skin tests and cardiovascular mortality and its subgroups was limited to subjects with both positive skin tests and asthma who had an increased risk for death from other cardiovascular disease (RR = 7.65; 95 percent CI: 1.61, 36.4).
Further analyses revealed that the association between eosinophilia and cardiovascular mortality was not different for subgroups of sex, age, smoking habits, body mass index, and city. Table 4 shows that the association between eosinophilia and cardiovascular mortality was limited to subgroups with FEV, percent predicted < 100 percent: subjects with eosinophilia had a 1.10 (95 percent CI: 0.70, 1.73) increased risk in the subgroup with FEVj percent predicted >100 percent, a 2.07 (RR = 1.1 x 1.88; 95 percent CI: 1.48, 2.89) increased risk in the subgroup with FEV, percent predicted 80-99.99 percent, and a 2.12 increased risk (RR = 1.1 x 1.94; 95 percent CI: 1.32, 3.43) in the subgroup with FEV, percent predicted <80 percent compared with subjects without eosinophilia. Although not statistically significant, the same pattern was present for mortality from ischemic and cardiovascular diseases other than ischemic heart disease and, within the subgroup of cardiovascular diseases other than ischemic heart disease, in the group of other cardiovascular disease.
The association between positive skin tests and cardiovascular death was different within subgroups of FEVj percent predicted, body mass index, and smoking but not within subgroups of sex and age. Subjects 2 ), or smoked, respectively. The same pattern was seen for mortality from ischemic and cardiovascular diseases other than ischemic heart disease and within the latter subgroup for death from other cardiovascular disease. Adjustment for the interaction between FEV, percent predicted and body mass index did not change these results.
Additional adjustment of the models in 
DISCUSSION
To our knowledge, this is the first large-scale study showing that eosinophilia is significantly associated with increased risk for cardiovascular death (RR = 1.7; 95 percent CI: 1.4, 2.2), not only with death from ischemic heart disease (RR = 1.6; 95 percent CI: 1.2, 2.2) but also with cerebrovascular disease death (RR = 2.3; 95 percent CI: 1.4, 3.8). This increased risk was restricted to subjects with a low or (near) normal lung function, that is, an FEV, <100 percent of predicted. Subjects with positive skin tests had a decreased risk of mortality from cardiovascular disease when they had normal weight and FEV, percent predicted >80 percent and did not smoke. In contrast, subjects with positive skin tests had an increased risk for cardiovascular mortality when they had one or more risk factors for cardiovascular mortality, that is, increased body mass index, FEV, percent predicted <80 percent, or smoking. Furthermore, these associations were present independent of a history of asthma attacks.
As far as we know, there is no literature on the relation between eosinophilia and cardiovascular death. Three studies have observed a higher incidence of ischemic heart disease with eosinophilia, including the first event of angina pectoris, myocardial infarction, or death due to ischemic heart disease (9, 10, 12) . These studies were all restricted to the incidence of ischemic heart disease within 5 years of follow-up. Our study extends these observations in that the association between eosinophilia and death due to ischemic heart disease is present during a maximum of 30 years of follow-up and after adjustment for other major risk factors for cardiovascular mortality. Thus, eosinophils may play a role in not only the incidence of but also the mortality from cardiovascular disease.
In this study eosinophilia was not only related to ischemic heart death but also strongly to cerebrovascu- lar death. The relation between eosinophilia and death from cerebrovascular disease has never been studied before. It is important to realize that, when we studied cerebrovascular death, we used all deaths due to cerebrovascular disease as the endpoint of interest (95 of 507 cardiovascular deaths) and considered all 412 other cardiovascular deaths as censored. Thus, the reference group included all subjects still alive, lost to follow-up, and dead from causes other than cerebrovascular disease, for example, cancer and ischemic heart disease. Therefore, the increased relative death risk of 2.2 due to cerebrovascular disease is even underestimated, because there were subjects with eosinophilia who had already died from ischemic heart disease. The predictive relation of a single risk factor, for example, eosinophilia, for cardiovascular mortality may reflect its association with other risk factors. It has long been recognized that the established risk factors male sex, older age, smoking (11), hypertension, hypercholesterolemia (1-4), overweight (3), and total leukocyte count (31) (32) (33) are associated with increased cardiovascular mortality, as well as low lung function (5, 6) . Data on hypercholesterolemia and hypertension were not available in this cohort study, yet that seems of little importance since we found no evidence in the literature that eosinophilia is associated with hypercholesterolemia or hypertension. In contrast, male sex, smoking, and low lung function (13, 14, 22) are all associated with eosinophilia. In this study, eosinophilia remained a risk factor, after controlling for smoking, only in subjects with an FEV, <100 percent of predicted.
Since the total leukocyte count is not available, we cannot rule out that the associations are a reflection of the known association of total leukocyte counts with cardiovascular disease (31) (32) (33) . In the 1960s the interest of the researchers focused on eosinophilia as an allergy marker and not as a part of the total leukocyte count, and they measured only the absolute eosinophil count. Only in the last follow-up in 1989/1990 of the young cohort, aged 15-39 years at the initial survey in 1967/1969, was the total leukocyte count also measured. The correlation coefficient between eosinophils and total leukocyte count was 0.24, which means that 0.78 of the variation in eosinophils was not explained by its association with total leukocyte counts. In addition, Prentice et al. (9) showed that, based on 79,274 total leukocyte and differential determinations, the average eosinophil fraction of the total leukocyte count was 2.8 percent. Since the eosinophil count constitutes only such a small fraction of the total leukocyte count, elevated eosinophil counts need not influence the total leukocyte count, and an increased total leukocyte count need not be caused by an increased eosinophil count. Therefore, we think that our results are not just a reflection of the association of total leukocyte count with cardiovascular disease.
Because of the relation between eosinophilia and both ischemic heart disease mortality and mortality from cerebrovascular disease, it seems plausible that eosinophils have a role in the endothelial inflammation of atherosclerosis. We suggest two potential mechanisms. First, Marone (34) proposed the mechanism that eosinophils can secrete among others eosinophil cationic protein and major basic protein, which can activate cardiac mast cells. These activated mast cells can then release histamine, which can result in coronary artery spasm and arrhythmias. This theory is in agreement with those of Hailgren et al. (35, 36) , who suggested the active participation of eosinophils in the inflammatory process in patients with acute myocardial infarction, and Trillo (37), who found eosinophils in the aortic fatty streaks of African green monkeys. Second, the enzyme arachidonate 15-lipoxygenase is expressed in significant quantities in eosinophils (38, 39) . This enzyme may be involved in oxidative modification of low density lipoprotein in the early phase of atherogenesis and may contribute to the development of atherosclerotic lesions (40) .
Subjects with positive skin tests, normal body weight, and (near) normal lung function who did not smoke had a decreased risk for total cardiovascular mortahty. However, when subjects with positive skin tests had an accumulation of other risk factors for cardiovascular mortality, especially obesity, low levels of lung function, or smoking, they had an increased risk of cardiovascular mortality. This is the first time that the relation between positive skin tests and mortality from cardiovascular disease has been investigated, and the results need confirmation. Rozencwaig (7) reported an increased incidence of heart disease in 50 allergic patients with positive allergy tests compared with 50 nonallergic patients. However, he did not mention explicitly that respiratory allergy was studied, and the results were not adjusted for lung function, body mass index, and smoking habits. His patients most likely had not only positive allergy tests but other risk factors for cardiovascular mortality that may have driven the results. We found that the presence of positive skin tests was not associated with cardiovascular mortality, after adjustment for its major risk factors (table  3) . This result is probably due to the high prevalence of overweight and obesity (almost 50 percent) and smoking (55 percent) in this population (table 1) . We can only speculate as to the mechanisms behind these associations. One explanation might be that positive skin tests are associated with other well-known risk factors for cardiovascular mortality for which we did not adjust in this study, that is, hypertension, hypercholesterolemia, physical inactivity, psychosocial factors, and diabetes mellitus. To our knowledge, however, there is no evidence of increased prevalence of these risk factors in subjects with positive skin tests.
Our study showed that body mass index, a wellknown risk factor for cardiovascular mortality (3), was not predictive by itself after taking into account its interaction with the presence of positive skin tests (table 4) . Furthermore, it seems that the association between impaired lung function and cardiovascular disease, which has been reported several times (5, 6), was partly mediated by the presence of allergy, manifested as both positive skin tests and eosinophilia. These observations point out new areas for research in the pathogenesis of cardiovascular disease for manifestations of allergy in combination with well-known risk factors for cardiovascular mortality.
In conclusion, our data suggest a possible link between the allergy markers, peripheral blood eosinophilia and positive skin tests, and cardiovascular mortality, both mortality of ischemic heart disease and cerebrovascular disease. These increased risks were present in combination with other risk factors, that is, reduced lung function in combination with eosinophilia and positive skin tests, and overweight and smoking in combination with positive skin tests. Weight reduction (41) and smoking cessation (42) have been shown to decrease the risk for cardiovascular death, and our results suggest that this can be especially important in individuals with positive skin tests. Nonallergic causes of eosinophilia seem to play an important role since the association remained unchanged after adjustment for positive skin tests and asthma
Since allergy increases in Western countries, our findings may have important implications for health economics and future mortality statistics. We recommend further research into the role of these allergy markers in the pathogenesis of cardiovascular disease to elucidate mechanisms for these epidemiologic associations.
